Compare FRPT & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRPT | AVDL |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2014 | 1996 |
| Metric | FRPT | AVDL |
|---|---|---|
| Price | $62.74 | $21.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 9 |
| Target Price | ★ $77.00 | $18.38 |
| AVG Volume (30 Days) | 1.0M | ★ 2.8M |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 169.38 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $1,079,494,000.00 | $248,517,000.00 |
| Revenue This Year | $15.47 | $65.47 |
| Revenue Next Year | $9.95 | $30.88 |
| P/E Ratio | $25.87 | ★ N/A |
| Revenue Growth | 16.34 | ★ 79.88 |
| 52 Week Low | $46.76 | $6.38 |
| 52 Week High | $164.07 | $23.57 |
| Indicator | FRPT | AVDL |
|---|---|---|
| Relative Strength Index (RSI) | 71.63 | 59.15 |
| Support Level | $56.28 | $21.32 |
| Resistance Level | $63.11 | $21.62 |
| Average True Range (ATR) | 2.12 | 0.34 |
| MACD | 0.91 | -0.31 |
| Stochastic Oscillator | 96.29 | 7.36 |
Freshpet produces and sells premium fresh pet food through its company-owned refrigerators placed in grocery, mass and club, pet specialty, and natural stores. Freshpet primarily targets dogs (96% of 2024 sales), with cats and treats comprising the rest of its sales. Geographically, the company's home US market, where all its food is produced, accounts for about 98% of sales, with exports to Canada, the United Kingdom, and other European countries accounting for the remaining balance.
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.